The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults

[1] Blennow O(2016)The challenge of antibiotic resistance in haematology patients Br J Haematol 172 497-511

[2] Ljungman P(2011)Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America Clin Infect Dis 52 e56-e93

[3] Freifeld AG(2009)Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 82-98

[4] Bow EJ(1993)Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies Clin Pharm 12 515-520

[5] Sepkowitz KA(2011)Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia Med Mal Infect 41 652-656

[6] Boeckh MJ(2014)Vancomycin dosing in neutropenic patients PLoS One 9 e112008-111

[7] Ito JI(2017)Neutropenia is independently associated with sub-therapeutic serum concentration of vancomycin Clin Chim Acta 465 106-710

[8] Mullen CA(2016)Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin Ther Drug Monit 38 706-49

[9] Raad II(2012)Survival in neutropenic patients with severe sepsis or septic shock Crit Care Med 40 43-5563

[10] Rolston KV(2010)Risk of mortality in patients with cancer who experience febrile neutropenia Cancer 116 5555-396

[1] Blennow O(2016)The challenge of antibiotic resistance in haematology patients Br J Haematol 172 497-511

[2] Ljungman P(2011)Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America Clin Infect Dis 52 e56-e93

[3] Freifeld AG(2009)Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 82-98

[4] Bow EJ(1993)Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies Clin Pharm 12 515-520

[5] Sepkowitz KA(2011)Vancomycin serum concentration during febrile neutropenia in patients with acute myeloid leukemia Med Mal Infect 41 652-656

[6] Boeckh MJ(2014)Vancomycin dosing in neutropenic patients PLoS One 9 e112008-111

[7] Ito JI(2017)Neutropenia is independently associated with sub-therapeutic serum concentration of vancomycin Clin Chim Acta 465 106-710

[8] Mullen CA(2016)Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin Ther Drug Monit 38 706-49

[9] Raad II(2012)Survival in neutropenic patients with severe sepsis or septic shock Crit Care Med 40 43-5563

[10] Rolston KV(2010)Risk of mortality in patients with cancer who experience febrile neutropenia Cancer 116 5555-396